• Frederick F. Becker

Part of the Cancer book series (C, volume 5)

Table of contents

  1. Front Matter
    Pages i-xxi
  2. General Principles of Chemotherapy

    1. Front Matter
      Pages 1-1
    2. Gerard T. Kennealey, Malcolm S. Mitchell
      Pages 3-27
    3. Gerald L. Schertz, John C. Marsh
      Pages 29-58
    4. Ed Cadman
      Pages 59-111
    5. Roland T. Skeel, Craig A. Lindquist
      Pages 113-143
    6. Michael T. Shaw, Robert D. Stebbins
      Pages 145-162
    7. L. Wayne Keiser, Robert L. Capizzi
      Pages 163-190
    8. W. Bruce Lundberg
      Pages 191-205
    9. William H. Greene
      Pages 223-282
  3. Chemotherapeutic Agents

    1. Front Matter
      Pages 283-283
    2. David B. Ludlum
      Pages 285-307
    3. G. A. LePage
      Pages 309-326
    4. Frank Maley
      Pages 327-361
    5. Bruce A. Chabner, David G. Johns
      Pages 363-377
    6. William A. Creasey
      Pages 379-425
    7. Irving H. Goldberg, Terry A. Beerman, Raymond Poon
      Pages 427-456
    8. Jack R. Uren, Robert E. Handschumacher
      Pages 457-487
    9. Willi Kreis
      Pages 489-519
    10. Ion Gresser
      Pages 521-571
    11. Kelly H. Clifton
      Pages 573-597
  4. Back Matter
    Pages 653-666

About this book


The promise of chemotherapeutic control in the field of oncology seemed, in the beginning, no less bright than it had proven in the field of bacterial disease, and, therefore, its failures were felt all the more. Despite the serendipitous discoveries and inspired insights which tantalized us with striking remissions, or the rare tumors which proved to be fully susceptible to a given agent, in the main, there has been either total failure or a painfully slow acquisition of an armamentarium against a limited number of malignancies. To expect more, however, was the result of ignorance of the malignant cell, for, as has been described in the previous volumes of this series, the exploitable differences between malignant and normal cells are few or undiscovered. "Differences" is the "numerator" in this formula, but "exploitable" is the operational term, for, although a great number of differences bet\\\een normal and malignant cells have been described, rarely are these differences observed in a vital metabolic pathway or a crucial macromolecu­ lar structure. Essentially, the basic metabolic pathways and nutritional require­ ments for :lOrmal and malignant cells are the same, resulting in the fact that no chemotherapeutic agent can successfully inhibit a function in the majority of malignant cells without adversely affecting a similar function in the normal cell. It was, therefore, naive to expect a "magic bullet" which would select the malignant cell and destroy it.


brain tumors breast cancer cancer cell chemotherapy classification clinical trial drug design hormones interferon leukemia lymphoma neuroblastoma oncology tumor

Editors and affiliations

  • Frederick F. Becker
    • 1
  1. 1.M.D. Anderson Hospital and Tumor InstituteUniversity of Texas System Cancer CenterHoustonUSA

Bibliographic information